UroGen Pharma Ltd.
DE ˙ DB ˙ IL0011407140
€ 23,18 ↑0.82 (3.67%)
2026-06-05
PREÇO DA AÇÃO
SecurityDE:UR8 / UroGen Pharma Ltd.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership370,898 shares
Latest Disclosed Value $ 6,668,746
Millennium Management Llc ownership in UR8 / UroGen Pharma Ltd.

On May 15, 2026 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 370,898 shares of UroGen Pharma Ltd. (DE:UR8) valued at $5,415,111 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 618,952 shares of UroGen Pharma Ltd.. This represents a change in shares of -40.08% during the quarter. The current value of the position is $8,597,416 USD.

Millennium Management Llc has a history of taking positions in derivatives of the underlying security (UR8) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:UR8 / UroGen Pharma Ltd. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F UROGEN PHARMA COM M96088105 370,898 -248,054 -40.08 6,669 -54.00 0.0028
2026-02-17 2025-12-31 13F UROGEN PHARMA COM M96088105 618,952 -849,785 -57.86 14,496 -50.53 0.0061
2025-11-14 2025-09-30 13F UROGEN PHARMA COM M96088105 1,468,737 874,706 147.25 29,301 260.05 0.0125
2025-08-14 2025-06-30 13F UROGEN PHARMA COM M96088105 594,031 170,446 40.24 8,138 73.74 0.0039
2025-05-15 2025-03-31 13F UROGEN PHARMA COM M96088105 423,585 -222,200 -34.41 4,685 -31.89 0.0025
2025-02-14 2024-12-31 13F UROGEN PHARMA COM M96088105 645,785 -853,416 -56.92 6,878 -63.88 0.0034
2024-11-14 2024-09-30 13F UROGEN PHARMA COM M96088105 1,499,201 338,302 29.14 19,040 -2.26 0.0090
2024-08-14 2024-06-30 13F UROGEN PHARMA COM M96088105 1,160,899 1,119,019 2,671.97 19,480 3,001.75 0.0090
2024-05-15 2024-03-31 13F UROGEN PHARMA COM M96088105 41,880 -384,626 -90.18 628 -90.18 0.0003
2024-02-14 2023-12-31 13F UROGEN PHARMA COM M96088105 426,506 150,721 54.65 6,398 65.60 0.0028
2023-11-14 2023-09-30 13F UROGEN PHARMA COM M96088105 275,785 83,657 43.54 3,864 94.32 0.0019
2023-08-14 2023-06-30 13F UROGEN PHARMA COM M96088105 192,128 -162,648 -45.85 1,989 -39.35 0.0010
2023-05-15 2023-03-31 13F UROGEN PHARMA COM M96088105 354,776 77,528 27.96 3,278 33.31 0.0019
2023-02-14 2022-12-31 13F UROGEN PHARMA COM M96088105 277,248 -162,274 -36.92 2,459 -32.76 0.0014
2022-11-14 2022-09-30 13F UROGEN PHARMA COM M96088105 439,522 -176,723 -28.68 3,657 -27.54 0.0022
2022-08-15 2022-06-30 13F UROGEN PHARMA COM M96088105 616,245 459,341 292.75 5,047 269.20 0.0031
2022-05-16 2022-03-31 13F UROGEN PHARMA COM M96088105 156,904 89,412 132.48 1,367 112.93 0.0007
2022-02-14 2021-12-31 13F UROGEN PHARMA COM M96088105 67,492 -1,195 -1.74 642 -44.42 0.0003
2021-11-15 2021-09-30 13F UROGEN PHARMA COM M96088105 68,687 4,887 7.66 1,155 18.58 0.0007
2021-08-16 2021-06-30 13F UROGEN PHARMA COM M96088105 63,800 -10,401 -14.02 974 -32.60 0.0006
2021-05-17 2021-03-31 13F UROGEN PHARMA COM M96088105 74,201 2,679 3.75 1,445 12.10 0.0010
2021-02-16 2020-12-31 13F UROGEN PHARMA COM M96088105 71,522 -18,186 -20.27 1,289 -25.49 0.0009
2020-11-16 2020-09-30 13F UROGEN PHARMA COM M96088105 89,708 -16,571 -15.59 1,730 -37.68 0.0021
2020-08-14 2020-06-30 13F UROGEN PHARMA COM M96088105 106,279 106,279 2,776 0.0038
2020-02-14 2019-12-31 13F UROGEN PHARMA COM M96088105 0 -10,855 -100.00 0 -100.00
2019-11-14 2019-09-30 13F UROGEN PHARMA COM M96088105 10,855 -79,513 -87.99 258 -92.06 0.0004
2019-08-15 2019-06-30 13F/A-1 UROGEN PHARMA COM M96088105 90,368 -9,526 -9.54 3,248 -11.98 0.0049
2019-08-14 2019-06-30 13F CF FIN ACQUISITION UNIT 04/30/2025 M96088105 400,000 300,106 4,140
2019-05-14 2019-03-31 13F UROGEN PHARMA COM M96088105 99,894 -9,998 -9.10 3,690 -22.02 0.0055
2019-02-15 2018-12-31 13F/A-1 UROGEN PHARMA COM M96088105 109,892 -123,461 -52.91 4,732 -57.06 0.0074
2019-02-14 2018-12-31 13F UROGEN PHARMA COM M96088105 109,892 4,732
2018-11-14 2018-09-30 13F UROGEN PHARMA COM M96088105 233,353 61,021 35.41 11,021 28.52 0.0135
2018-08-14 2018-06-30 13F UROGEN PHARMA COM M96088105 172,332 13,219 8.31 8,575 8.46 0.0112
2018-05-15 2018-03-31 13F UROGEN PHARMA COM M96088105 159,113 147,628 1,285.40 7,906 1,751.52 0.0105
2018-02-14 2017-12-31 13F UROGEN PHARMA COM M96088105 11,485 11,485 427 0.0006
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-17 2025-12-31 13F UROGEN PHARMA COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-14 2025-09-30 13F UROGEN PHARMA COM Call 45,000 0.22 898 45.85 n/a n/a n/a
2025-08-14 2025-06-30 13F UROGEN PHARMA COM Call 44,900 615 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.